New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:04 EDTDPRXDipexium Pharmaceuticals begins Phase 3 clinical trial of Locilex for foot ulcer
Dipexium Pharmaceuticals has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials evaluating Locilex, the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The FDA has agreed to a Special Protocol Assessment with Dipexium for Locilex's pivotal Phase 3 clinical trial program in Mild DFI.
News For DPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
09:13 EDTDPRXDipexium Pharmaceuticals 1.48M share Spot Secondary priced at $12.50
The deal size was increased to 1.48M shares from 1.38M shares. Raymond James acted as sole book running manager for the offering.
June 24, 2015
16:04 EDTDPRXDipexium Pharmaceuticals files to sell common stock, no amount given
The Company intends to use the net proceeds from the offering to fund its operations and for other general corporate purposes, including, but not limited to, its internal research and development programs and the development of new programs and general working capital. Raymond James & Associates, Inc. is acting as sole book-running manager for the offering. Feltl and Company is acting as co-manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use